SCHEDULE 13G/A: Tybourne Capital Management Discloses Near 10% Stake in Forte Biosciences

Tybourne Capital Management and its affiliates have filed an amended Schedule 13G, revealing a 9.99% beneficial ownership stake in Forte Biosciences, Inc. as of December 31, 2024.

Summary

• Tybourne Capital Management (HK) Ltd, Tybourne Strategic Opportunities GP II Limited, Tybourne Capital Management Ltd, Tybourne Kesari Ltd, and Krishnan Viswanathan (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 640,770 shares of Common Stock in Forte Biosciences, Inc.
• This aggregate amount represents 9.99% of Forte Biosciences' outstanding Common Stock.
• The Reporting Persons hold shared voting power and shared dispositive power over all 640,770 shares.
• The reported shares include 619,981 shares of Common Stock and 20,789 shares issuable upon the exercise of pre-funded warrants.
• The pre-funded warrants held by the Private Funds could be exercisable for up to an aggregate of 739,147 shares of Common Stock, but their exercise is limited to prevent beneficial ownership from exceeding 9.99% of the outstanding shares.
• The percentage ownership is calculated based on 6,393,323 shares of Common Stock outstanding as of December 30, 2024, as stated in the Issuer's proxy statement.
• The share numbers in the filing reflect a 1:25 reverse stock split effected by Forte Biosciences in August 2024.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, typical for a Schedule 13G filing. It does not contain positive or negative performance indicators or forward-looking statements from the issuer.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive investment by an institutional fund in a publicly traded company. It does not provide specific insights into broader industry trends but indicates an investment firm's confidence or strategic positioning within the biotechnology or pharmaceutical sector, where Forte Biosciences operates.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.99%) by Tybourne Capital Management could be viewed positively by other shareholders as it signals confidence from a professional investor, potentially increasing liquidity or stability for the stock. However, the filing explicitly states the investment is for ordinary course of business and not for control, which might temper expectations of activist involvement.

Key Dates

Keywords

Forte Biosciences, Tybourne Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Pre-funded Warrants, SEC Filing